Johan Sandell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johan Sandell has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Christer Halldin
4 shared publications- Christer Halldin
Department of Biophysics and Radiation Biology, HUN-REN TKI, Semmelweis University, 1094 Budapest, Hungary
4 shared publications - Lars Farde
Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, S‐17176 Stockholm, Sweden
4 shared publications - Patrick Emond
UMR 1253, iBrain, University of Tours, Inserm, 37044 Tours, France
4 shared publications - Oliver Langer
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
3 shared publications - Balázs Gulyás
Cognitive Neuroimaging Centre, Experimental Medicine, Nanyang Technological University, Singapore 636921, Singapore
2 shared publications
Latest Publications
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S126
[18F]AZD4694—A new PET radioligand for sensitive detection of β-amyloid deposits
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S126
[18F]AZD4694—A new PET radioligand for sensitive detection of β-amyloid deposits
- 1 December 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (24) , 3611-3613
Synthesis, radiolabeling and preliminary biological evaluation of radiolabeled 5-methyl-6-nitroquipazine, a potential radioligand for the serotonin transporter
- 1 December 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (24) , 3611-3613
Synthesis, radiolabeling and preliminary biological evaluation of radiolabeled 5-methyl-6-nitroquipazine, a potential radioligand for the serotonin transporter
- 24 November 2002
- Vol. 143 (47) , 2631-6
[Cerebral uptake and regional distribution of [11C]-vinpocetin after intravenous administration to healthy men: a PET study].
Vinpocetine is a compound widely used in the prevention and treatment of cerebrovascular diseases. The exact mechanism of action of the drug is still not known. The objective of the present investigation was to determine the global uptake and regional distribution of radiolabelled vinpocetine in the human brain. Three healthy persons were examined with positron emission tomography (PET) and [11C]-vinpocetine. The uptake of [11C]-vinpocetine in brain was rapid and on average as a maximum 3.7% of the total radioactivity injected was in the brain 2 minutes after radioligand administration. The uptake was heterogeneously distributed among brain regions. When compared with the cerebellum, an a priori reference region, the highest regional uptake was in the thalamus, the upper brain stem, the striatum and the cortex. The brain regions showing increased uptake in the human brain correspond to those in which vinpocetine has previously been shown to induce elevated metabolism and blood flow by PET clinical studies in patients with chronic ischaemic post-stroke condition.
- 24 November 2002
- Vol. 143 (47) , 2631-6
[Cerebral uptake and regional distribution of [11C]-vinpocetin after intravenous administration to healthy men: a PET study].
Vinpocetine is a compound widely used in the prevention and treatment of cerebrovascular diseases. The exact mechanism of action of the drug is still not known. The objective of the present investigation was to determine the global uptake and regional distribution of radiolabelled vinpocetine in the human brain. Three healthy persons were examined with positron emission tomography (PET) and [11C]-vinpocetine. The uptake of [11C]-vinpocetine in brain was rapid and on average as a maximum 3.7% of the total radioactivity injected was in the brain 2 minutes after radioligand administration. The uptake was heterogeneously distributed among brain regions. When compared with the cerebellum, an a priori reference region, the highest regional uptake was in the thalamus, the upper brain stem, the striatum and the cortex. The brain regions showing increased uptake in the human brain correspond to those in which vinpocetine has previously been shown to induce elevated metabolism and blood flow by PET clinical studies in patients with chronic ischaemic post-stroke condition.
- 1 August 2002
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 29 (6) , 651-656
PET examination of [11C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter
- 1 August 2002
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 29 (6) , 651-656
PET examination of [11C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter
- 2 November 2001
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 44 (14) , 1013-1023
Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter
- 2 November 2001
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 44 (14) , 1013-1023
Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter
- 15 October 2000
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 43 (11) , 1069-1074
Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756
- 15 October 2000
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 43 (11) , 1069-1074
Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756
- 1 September 2000
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 43 (10) , 1033-1046
Synthesis of [11C]2?-carbomethoxy-3?-(3?-iodo-4?-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography
- 1 September 2000
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 43 (10) , 1033-1046
Synthesis of [11C]2?-carbomethoxy-3?-(3?-iodo-4?-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography
- 30 March 2000
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 43 (4) , 331-338
Improved specific radioactivity of the PET radioligand [11C]FLB 457 by use of the GE medical systems PETtrace MeI microlab
- 30 March 2000
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 43 (4) , 331-338
Improved specific radioactivity of the PET radioligand [11C]FLB 457 by use of the GE medical systems PETtrace MeI microlab
- 22 December 1999
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 42 (12) , 1183-1193
Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate
- 22 December 1999
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 42 (12) , 1183-1193
Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate
- 1 June 1998
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 41 (6) , 545-556
Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β-CIT-FE, by the use of [11C]methyl triflate
- 1 June 1998
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 41 (6) , 545-556
Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β-CIT-FE, by the use of [11C]methyl triflate